Saba Rouhani

Assistant Professor of Epidemiology

Professional overview

Dr. Saba Rouhani is an Assistant Professor in the Department of Epidemiology at GPH, and joins the school as inaugural faculty at its Center for Anti-racism, Social Justice and Public Health.

Her research is focused on characterizing the structural environment that influences the risk of overdose and other drug-related harms; she investigates the impact of harm reduction and overdose prevention initiatives, using results to identify gaps in implementation and to inform policy. Dr. Rouhani is especially interested in how drug policy has fueled mass incarceration and impacted racial and ethnic minorities in the United States, and she studies how changes to the policy and policing landscape may promote or hinder equity in health and social outcomes. Her current research is focused on characterizing emerging drug decriminalization policies and modeling their impacts on equity in criminal legal involvement and health outcomes.

Prior to joining NYU Dr. Rouhani worked as research faculty in the Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health. She also completed a fellowship funded by the National Institutes of Health/National Institute on Drug Abuse. Her research has been published in the International Journal of Drug Policy, Drug and Alcohol Dependence, the Journal of Urban Health, and the American Journal of Public Health and Preventive Medicine.

Dr. Rouhani received her PhD in global disease epidemiology and control from the Johns Hopkins Bloomberg School of Public Health. She holds an MSc in the control of infectious diseases from the London School of Hygiene and Tropical Medicine, and a BSc in medical microbiology from the University of Edinburgh.

Education

PhD Global Disease Epidemiology & Control, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

MS Control of Infectious Diseases, The London School of Hygiene & Tropical Medicine, London, United Kingdom

BS Medical Microbiology, University of Edinburgh, Edinburgh, United Kingdom

Honors and awards

Drug Dependency Epidemiology Training (T32) Fellowship, National Institute of Drug Abuse, National Institutes of Health (2018)

The R. Bradley Sack Family Scholarship Award, Johns Hopkins Bloomberg School of Public Health (2016)

Global Health Established Field Placement Scholarship, Johns Hopkins Bloomberg School of Public Health (2014)

Save the Children Program Management Award, Save the Children International (2012)

Royal Society of Tropical Medicine and Hygiene Award for Best Poster Presentation of Research in Progress (2012)

Publications

Publications

Norovirus infection and acquired immunity in 8 countries: Results from the MAL-ED study

Failed generating bibliography.

Publication year

2016

Journal title

Clinical Infectious Diseases

Volume

62

Issue

10

Page(s)

1210-1217

10.1093/cid/ciw072

Abstract

Abstract

Background. Norovirus is an important cause of childhood diarrhea. We present data from a longitudinal, multicountry study describing norovirus epidemiology during the first 2 years of life. Methods. A birth cohort of 1457 children across 8 countries contributed 7077 diarrheal stools for norovirus testing. A subset of 199 children contributed additional asymptomatic samples (2307) and diarrheal stools (770), which were used to derive incidence rates and evaluate evidence for acquired immunity. Results. Across sites, 89% of children experienced at least 1 norovirus infection before 24 months, and 22.7% of all diarrheal stools were norovirus positive. Severity of norovirus-positive diarrhea was comparable to other enteropathogens, with the exception of rotavirus. Incidence of genogroup II (GII) infection was higher than genogroup I and peaked at 6-11 months across sites. Undernutrition was a risk factor for symptomatic norovirus infection, with an increase in 1 standard deviation of length-for-age z score associated with a 17% reduction (odds ratio, 0.83 [95% confidence interval,. 72-.97]; P =. 011) in the odds of experiencing diarrhea when norovirus was present, after accounting for genogroup, rotavirus vaccine, and age. Evidence of acquired immunity was observed among GII infections only: Children with prior GII infection were found to have a 27% reduction in the hazard of subsequent infection (hazard ratio, 0.727; P =. 010). Conclusions. The high prevalence of norovirus across 8 sites in highly variable epidemiologic settings and demonstration of protective immunity for GII infections provide support for investment in vaccine development.